TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33422245
Drug: Sanofi Pasteur
Normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanofi Pasteur standard dose
Study: 33422245
Drug: Sanofi Pasteur
Normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanofi Pasteur fractional dose
Study: 34059348
Drug: Intervention (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (3 standardized CBT‐based sessions in the 6–12 weeks post‐chemotherapy)
Study: 32321161
Drug: High Breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Breakfast (HBR) group, n=12, protein intake at breakfast: 0.33 g/kg BW, lunch: 0.46 g/kg BW, dinner: 0.48 g/kg BW, total daily protein intake: 1.30 g/kg BW/d
Study: 32321161
Drug: Low Breakfast
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Breakfast (LBR) group, n=14, protein intake at breakfast: 0.12 g/kg BW, lunch: 0.45 g/kg BW, dinner: 0.83 g/kg BW, total daily protein intake: 1.30 g/kg BW/d
Study: 38664701
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical care
Study: 34656876
Drug: Aviandr 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviandr 40 mg daily
Study: 34656876
Drug: Aviandr 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviandr 60 mg daily
Study: 34656876
Drug: Aviandr (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviandr (both doses)
Study: 34783456
Drug: Generic budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Generic budesonide nasal spray (256 μg)
Study: 34783456
Drug: Branded budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Branded budesonide nasal spray (256 μg)
Study: 34074263
Drug: Randomized test‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized test‐treatment studies
Study: 34074263
Drug: Adaptive designs
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive designs within randomized test‐treatment studies
Study: 32762394
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid treatment
Study: 32492377
Drug: CSP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSP with submucosal injection (CSP-SI)
Study: 33026895
Drug: Control (FES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (FES treatment and conventional physical therapy)
Study: 34979180
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (n = 318)
Study: 36107590
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg/kg) intramuscularly injected 30 minutes before general anesthesia
Study: 32971314
Drug: Continuation cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation cognitive therapy (CT)
Study: 32967726
Drug: Electrolyte supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte supplementation (Magnesium, Calcium, and Potassium) with intravenous normal saline
Study: 36263238
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 0.6 mg/kg rocuronium based on Total Body Weight (TBW) in Group 1K
Study: 35570929
Drug: Avelumab maintenance
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab maintenance therapy (AVE group)
Study: 33748529
Drug: Control mattress
Normalized name: PADS,MATTRESS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control mattress (treatment as usual; TAU): non‐oscillating hospital‐crib mattress
Study: 33748529
Drug: Control mattress
Normalized name: PADS,MATTRESS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control mattress (treatment as usual; TAU)
Study: 32595082
Drug: Antipsychotic polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polypharmacy (two or more co-prescribed antipsychotic drugs)
Study: 35253776
Drug: Structured Medication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Medication Review (SMR)
Study: 38231511
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Medication Management (MEDS)
Study: 33092897
Drug: Wii training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii training in addition to traditional therapy
Study: 33109663
Drug: Iodinated oil
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodinated oil injection (OSCM group, oil-soluble contrast media)
Study: 33109663
Drug: Ioversol injection
Normalized name: Ioversol
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ioversol injection (WSCM group, water-soluble contrast media)
Study: 33109663
Drug: Iodinated oil
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodinated oil injection (OSCM group)
Study: 35215501
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements based on L-Theanine and Vitamin B6
Study: 35073989
Drug: 1 +
Normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 + 1 schedule (one dose at 6 weeks and a booster at 9 months)
Study: 35073989
Drug: 3 +
Normalized name: D3 + K2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 + 0 schedule (three doses at 6, 10, and 14 weeks)
Study: 33783399
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 36 IU (3 sprays) twice a day
Study: 33783399
Drug: Intranasal placebo-oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo-oxytocin (3 sprays) twice a day
Study: 34481326
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) nasal spray
Study: 32750332
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) nasal spray
Study: 32926462
Drug: Baricitinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (2 mg)
Study: 34032934
Drug: Personalized pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Personalized pharmaceutical plan with a 30-min opioid-targeted pharmaceutical interview
Study: 35538479
Drug: E2/NOMAC (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NOMAC (1.5 mg 17β-estradiol + 2.5 mg nomegestrol acetate)
Study: 35538479
Drug: DNG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNG (2 mg/daily dienogest)
Study: 32101302
Drug: Skin Self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin Self-monitoring (SSM) smartphone application with monthly self-monitoring reminders
Study: 32739072
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene program combined with home-phone health promoting counseling
Study: 35740202
Drug: Ivermectin (400–600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400–600 µg/kg/d)
Study: 36267612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hyperbaric bupivacaine (0.5%)
Study: 36267612
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of hyperbaric bupivacaine (0.5%)
Study: 33597131
Drug: ACC/AHA 2017
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC/AHA 2017 guideline recommendation for antihypertensive medication
Study: 33597131
Drug: JNC7 guideline
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNC7 guideline recommendation for antihypertensive medication
Study: 33597131
Drug: ESH/ESC 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESH/ESC 2013 guideline recommendation for antihypertensive medication
Study: 33597131
Drug: ESC/ESH 2018
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESC/ESH 2018 guideline recommendation for antihypertensive medication
Study: 33597131
Drug: WHO/ISH 2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO/ISH 2003 guideline recommendation for antihypertensive medication
Study: 33597131
Drug: ISH 2020
Normalized name: ALCOHOL 45 mL in 60 mL EXTRACORPOREAL GEL [ishine hand sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISH 2020 guideline recommendation for antihypertensive medication
Study: 32246196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychoeducation and cognitive behavioral therapy (CBT)
Study: 32246196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychoeducation and CBT
Study: 33720588
Drug: Polydexa with
Normalized name: Lydexa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydexa with phenylephrinum (topical nasal spray)
Study: 33720588
Drug: Systemic antibacterial
Normalized name: Trimethoprim and derivatives, systemic antibacterials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibacterial therapy and long‐acting local decongestants
Study: 33823786
Drug: Group TAP
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group TAP (20 mL of 0.5% ropivacaine per side)
Study: 34862870
Drug: Amiodarone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone combined with atorvastatin
Study: 35411186
Drug: Low Serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Serratus Anterior Plane Block (SAPB) with 40 mL 0.375% ropivacaine
Study: 35413933
Drug: HCV self-testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV self-testing via online distribution (oral fluid- or blood-based HCV self-test kit mailed)
Study: 35413933
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (clinic-based HCV antibody testing)
Study: 36005503
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day SXRG84 for six weeks
Study: 36005503
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day SXRG84 for six weeks
Study: 36005503
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for six weeks followed by 2 g/day SXRG84 for six weeks (Study 2)
Study: 34654349
Drug: ZSP1273 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 (single or multiple doses)
Study: 32240370
Drug: Parent Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Child Interaction Therapy Emotion Development (PCIT-ED)
Study: 34628482
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg JNJ-48816274
Study: 34628482
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg JNJ-48816274
Study: 32658921
Drug: Cryotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy treatment for hrHPV positive women
Study: 32658921
Drug: Provider perceptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider perceptions of barriers to treatment
Study: 32658921
Drug: Facilitators of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitators of treatment
Study: 34336894
Drug: Anaprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaprazole 20 mg
Study: 34336894
Drug: Anaprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaprazole 40 mg
Study: 32987282
Drug: Symptom severity
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom severity (self- and rater assessed at beginning and end of therapy)
Study: 33784487
Drug: FitSkills exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: FitSkills exercise program (12 weeks, twice-weekly sessions)
Study: 35035429
Drug: Lipid based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid based nutritional supplement for pregnant and lactating women LNS-PLW
Study: 35614509
Drug: Multicomponent LIVE
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent LIVE intervention (including medication review by the PwD’s regular GPs)
Study: 34889235
Drug: modified GGQL
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified GGQL formula plus basic antitumor therapy
Study: 34889235
Drug: basic antitumor
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic antitumor therapy
Study: 34197772
Drug: Emtricitabine and
Normalized name: emtricitabine and tenofovir alafenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine and tenofovir alafenamide (200/25 mg)
Study: 34197772
Drug: Emtricitabine and
Normalized name: emtricitabine and tenofovir alafenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine and tenofovir disoproxil fumarate (200/300 mg)
Study: 33017685
Drug: Retrograde filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde filling of the bladder with 200 mL of saline before catheter removal
Study: 32856785
Drug: Postoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concurrent aerobic and resistance training for 12 weeks
Study: 36079794
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day n3-PUFA
Study: 35598544
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of saccharin
Study: 35598544
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of water
Study: 35657320
Drug: ctDNA-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA-positive patients receiving adjuvant chemotherapy
Study: 35657320
Drug: ctDNA-negative patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA-negative patients not receiving adjuvant chemotherapy
Study: 35487736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of light acupuncture treatment and five-element music therapy
Study: 35487736
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment group
Study: 36153330
Drug: TAK-653 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-653 0.5 mg
Study: 36153330
Drug: TAK-653 6
Normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-653 6 mg
Study: 33433363
Drug: Anticipated delay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticipated delay in help-seeking for rectal bleeding
Study: 35210132
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg lenvatinib plus everolimus 5 mg/d
Study: 35210132
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg lenvatinib plus everolimus 5 mg/d
Study: 33626290
Drug: Dengue vaccine
Normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue vaccine booster
Study: 35797300
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% and Fusidic acid 2% cream
Study: 34054104
Drug: 4‐μg E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐μg E2 vaginal insert
Study: 34054104
Drug: 10‐μg E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐μg E2 vaginal insert
Study: 32762415
Drug: Pembrolizumab (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (first-line treatment)
Study: 35641166
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) transplantation of mesenchymal stem cells (MSC)
Study: 34377204
Drug: Intravenous eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous eptifibatide before angioplasty with heparin
Study: 34377204
Drug: Coronary angioplasty
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary angioplasty with heparin
Study: 36034460
Drug: LH-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-based modified GnRH antagonist protocol
Study: 36034460
Drug: Conventional flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional flexible GnRH antagonist protocol
Study: 33238932
Drug: Mindfulness oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness oriented intervention (6 weeks of mindfulness training combined with interactive drug education)
Study: 34755786
Drug: Chincup (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chincup (CC)
Study: 33050586
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of Fermented Porcine Placental Extract (FPP) once daily
Study: 34117637
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication (specifics not provided)
Study: 35636937
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of melatonin prolonged-release oral capsules
Study: 32689975
Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) single tablet regimen
Study: 32689975
Drug: Boosted protease-inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease-inhibitor (bPI) regimen
Study: 33444178
Drug: 8-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week group art therapy intervention
Study: 36027380
Drug: Short-acting RAS
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting RAS blockers taken on awakening
Study: 36027380
Drug: Short-acting RAS
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting RAS blockers taken at bedtime
Study: 37759290
Drug: Automated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Insulin Delivery (AID) devices
Study: 33884645
Drug: Trophic enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic enteral feeding (20 ml/h) via a nasogastric tube, in addition to standard care.
Study: 33884645
Drug: Standard nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutrition care (parenteral nutrition).
Study: 35720885
Drug: Laparoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic treatment (observation group)
Study: 35720885
Drug: Open surgical
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgical treatment (control group)
Study: 32648508
Drug: PDE‐5 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE‐5 inhibitors (PDE‐5i)
Study: 32648508
Drug: No PDE‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PDE‐5 inhibitors (no PDE‐5i)
Study: 36447250
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) combined with eccentric exercises
Study: 35659064
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg oleoylethanolamide (OEA) capsule daily for 8 weeks
Study: 35659064
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg capsule containing wheat flour (placebo) daily for 8 weeks
Study: 34045217
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review at hospital discharge combined with communication stimulus between hospital physicians and general practitioners
Study: 32237922
Drug: Cranberry supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry supplement (288 mg equivalent to 26 g of dried cranberry)
Study: 35320892
Drug: Durvalumab 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1,500 mg q4w + Pegylated liposomal doxorubicin (PLD) or Topotecan or Weekly Paclitaxel (arm 3)
Study: 35320892
Drug: Durvalumab 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1,500 mg q4w + Tremelimumab 75mg q4w + PLD or Topotecan or Weekly Paclitaxel (arm 4)
Study: 35320892
Drug: Durvalumab 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1,500 mg q4w + Tremelimumab 300mg [1 dose] + Weekly Paclitaxel [60 mg/m² D1,8,15 q4w for 4 cycles] (arm 5)
Study: 37850681
Drug: Anti-seizure medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-seizure medications
Study: 35114331
Drug: Standard Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oral Hygiene Advice (OHA) with intra-oral camera (IOC) images
Study: 35114331
Drug: Standard Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oral Hygiene Advice (OHA)
Study: 34158427
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 15 mg/kg (Group M)
Study: 35970278
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of IV tranexamic acid preoperatively
Study: 33991337
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of diesel exhaust particles (DEP) at nontoxic concentrations
Study: 33991337
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of an antioxidant mixture
Study: 35054157
Drug: Liposomal fat-soluble
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal fat-soluble vitamin formulation containing vitamin K2 (2667 IU vitamin A, 1333 IU beta-carotene, 4000 IU D3, 150 IU E, 2 mg K1, 400 μg K2)
Study: 35054157
Drug: Liposomal fat-soluble
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal fat-soluble vitamin formulation containing vitamin K2